Acute Care Implications of the 2026 NICE T2DM Update

What EM, CCM and Acute Physicians Must Now Expect

The 2026 revision of NICE NG28 represents a paradigm shift:
glucose-lowering therapy is now anchored to cardio-renal protection, not simply glycaemic control. As a result, the drug profiles of patients presenting to ED/ICU might fundamentally changed.

---

1. SGLT-2 Inhibitors as Foundational Therapy

What has changed

SGLT-2 inhibitors are now recommended first-line (with metformin) across:

• No comorbidity

• Heart failure

• ASCVD

• CKD (down to eGFR 20)

• Early-onset T2DM

• Obesity

Acute Care Relevance

1.1 Expect near-universal exposure

A large proportion of T2DM patients presenting to ED will be on:

• Empagliflozin

• Dapagliflozin

This includes patients with:

• Advanced CKD (eGFR 20–30, combined with DPP-4 inhibitor)

  type-2-diabetes-in-adults-manag…

• Heart failure with preserved or reduced EF

• ASCVD on triple therapy

1.2 Increased Risk of Eu-glycaemic DKA

The guideline explicitly:

• Requires DKA risk assessment before starting SGLT-2

• Advises suspension during ketogenic diets and intercurrent illness

EM/ICU Translation

Lower threshold to:

• Check blood ketones in:

  • Sepsis

  • Major surgery

  • AKI

  • Reduced oral intake

  • Steroid therapy

• Diagnose DKA despite glucose <250 mg/dL

• Stop SGLT-2 immediately on admission if:

  • Shock

  • Hypoxia

  • AKI

  • Severe infection

  • Peri-operative state

Clinical shift: Hyperglycaemia is no longer required to suspect DKA.

2. Sick-Day Rules Become Mandatory Documentation

The updated guideline mandates explicit sick-day plans including temporary cessation of:

• Metformin

• SGLT-2 inhibitors

Acute Care Implication

In ED/ICU you are now:

• Justified in holding these agents in:

  • Dehydration

  • Hypotension

  • Sepsis

  • Contrast exposure

• Expected to document:

  • When to restart

  • Under what renal/hemodynamic parameters

Metformin: Stop in hypoxia, shock, significant AKI (lactic acidosis risk).
SGLT-2: Stop early in any catabolic or volume-depleted state.

3. Advanced CKD Patients Will Still Be on SGLT-2

The update allows:

• Dapagliflozin or empagliflozin down to eGFR 20

• Combination with DPP-4 inhibitor between eGFR 20–30

EM/ICU Implications

You will encounter:

• Dialysis-adjacent patients still taking SGLT-2

• Lower baseline glucose but ongoing osmotic diuresis risk

Monitor for:

• Volume depletion

• Hypotension

• AKI worsening

• Electrolyte shifts

4. Early Triple Therapy is Now Common

For ASCVD, obesity, and early-onset T2DM:

• Metformin

• SGLT-2 inhibitor

• GLP-1 RA or tirzepatide

ICU Implications

Expect:

• Lower HbA1c but polypharmacy

• Reduced insulin requirements at baseline

• Higher GI side-effect burden

5. GLP-1 Receptor Agonists & Tirzepatide in Acute Care

Recommended strongly for ASCVD and obesity

Acute Care Consequences

5.1 Delayed Gastric Emptying

Implications:

• Increased aspiration risk

• Nausea/vomiting complicating NIV tolerance

• Enteral feeding delays

5.2 Peri-intubation considerations

Consider:

• Full stomach assumption

• RSI preference in unstable patients

6. Glucose Monitoring: Acute Illness and Steroids

The guideline emphasizes:

• Acute intercurrent illness increases hyperglycaemia risk

• Short-term capillary monitoring is appropriate during steroid initiation

EM/ICU Translation

Expect:

• Marked steroid-induced hyperglycaemia

• Rapid escalation of insulin requirements

• Need for structured monitoring post-discharge

Steroid-treated pneumonia/COPD patients will frequently require:

• Basal-bolus insulin

• Escalated capillary monitoring

7. Continuous Glucose Monitors (CGM) Use Will Increase in Hospital

Clear endorsement of:

• isCGM

• rtCGM in insulin-treated T2DM with recurrent/severe hypoglycaemia

Acute Care Implications

You will see:

• CGM sensors in admitted patients

Important:

• Do NOT rely solely on CGM in:

  • Shock

  • Rapid glucose change

  • Vasopressor states

• Capillary testing remains required for accuracy confirmation.

Ensure:

• Backup strips are available

• Device knowledge confirmed at discharge

8. Organ-Protection Bias Over Glycaemia

The guideline states that SGLT-2 and GLP-1 RAs are recommended as much for CV/renal benefit as glycaemia

Critical Care Reframing

When rationalising medications in ICU:

Do not interpret normal HbA1c as overtreatment.

Instead:

• Distinguish glycaemic drugs from organ-protective drugs

• Restart SGLT-2 and GLP-1 early once:

  • Hemodynamically stable

  • Renal function recovered

  • Oral intake adequate

These are now secondary prevention agents.

9. Frailty and Hypotension Risk

For frail adults:

• SGLT-2 only if low risk of volume depletion/hypotension

ED/ICU Implication

In elderly septic patients:

• SGLT-2 may contribute to:

  • Pre-existing volume contraction

  • Orthostatic collapse

  • AKI

High vigilance for polypharmacy-related hypotension.

10. Peri-Operative and Critical Care Protocol Adjustments

Because SGLT-2 use is now foundational:

Every diabetic ICU admission should trigger:

• Medication reconciliation focused on SGLT-2

• Ketone surveillance if acidosis

• Clear peri-operative cessation plan

The era of “metformin only” diabetics is over.

Start/stop decision plan in EM/Acute care

Bedside decision algorithm - for stop/restart of DM drugs in acute care.

For more such updates-
Follow on instagram

References-
NICE 2026 update on T2DM